Advanced Fibrolamellar Carcinoma
1 clinical trials · Condition
◉ Watch Advanced Fibrolamellar Carcinoma
| Record | Firm | Date |
|---|---|---|
| A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma (NCT02234986) | CASI pharmaceuticals, Inc. | 2015-10-01 |
Track Advanced Fibrolamellar Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.